[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP2013545730A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545730A5
JP2013545730A5 JP2013535311A JP2013535311A JP2013545730A5 JP 2013545730 A5 JP2013545730 A5 JP 2013545730A5 JP 2013535311 A JP2013535311 A JP 2013535311A JP 2013535311 A JP2013535311 A JP 2013535311A JP 2013545730 A5 JP2013545730 A5 JP 2013545730A5
Authority
JP
Japan
Prior art keywords
compound
neuropathic pain
pain
syndrome
lesions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013535311A
Other languages
English (en)
Other versions
JP6257326B2 (ja
JP2013545730A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/005452 external-priority patent/WO2012055567A2/en
Publication of JP2013545730A publication Critical patent/JP2013545730A/ja
Publication of JP2013545730A5 publication Critical patent/JP2013545730A5/ja
Application granted granted Critical
Publication of JP6257326B2 publication Critical patent/JP6257326B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (11)

  1. 神経因性疼痛及び/又は神経因性疼痛症候群の治療において使用するための化合物であって、
    前記化合物は、化学式:
    又は、化学式:
    で示されるマロノニトリルアミド化合物、又は、その薬学的に許容される塩、溶媒和物、互変異性体若しくは立体異性体である化合物。
  2. 請求項に記載の化合物において、
    前記化合物の互変異性体は、ケト型又はエノール型の2−シアノ−3−オキソ−N−[4−(トリフルオロメチル)フェニル]−6−ヘプチンアミドである化合物。
  3. 請求項1又は2に記載の化合物において、
    前記化合物の立体異性体は、R鏡像異性体又はS鏡像異性体である化合物。
  4. 請求項1〜のいずれか1項に記載の化合物において、
    前記化合物は、末梢の及び/又は主に末梢の神経因性疼痛、又は、中枢の及び/又は主に中枢の神経因性疼痛の治療において使用される化合物。
  5. 請求項に記載の化合物において、
    前記主に末梢の神経因性疼痛は、以下の神経因性疼痛の種類から選ばれる種類であるか、及び/又は以下の病因群から選ばれる病因を有し、
    −全身性疾患、
    −薬物誘発性病変、
    −外傷性症候群及び絞扼性神経障害、
    −神経根及び後神経節における病変、
    −HIV感染後の神経障害、
    −ヘルペス感染後の神経痛、
    −神経根引き抜き損傷、
    −脳神経病変、
    −頭蓋神経痛、
    −神経因性癌疼痛、
    −幻肢痛、
    −末梢神経、神経叢及び神経根の圧迫、
    −腫瘍随伴性末梢神経障害及び神経節障害、
    −癌治療による合併症、
    −複合性局所疼痛症候群、
    −I型病変、
    −II型病変、
    前記主に中枢の神経因性疼痛は、
    −主に視床の脳病変、
    −梗塞、
    −視床や脳幹を圧迫する脳の腫瘍又は膿瘍、
    −多発性硬化症、
    −頭痛症候群、
    −脳手術、
    −脊髄障害、
    −脊髄損傷、
    −脊髄手術、
    −虚血性病変、
    −前脊髄動脈症候群、
    −ワレンベルグ症候群、
    −脊髄空洞症、
    などの病因群から選ばれる病因を有するタイプのものである化合物。
  6. 請求項1〜のいずれか1項に記載の化合物において、
    前記神経因性疼痛症候群は、帯状疱疹後神経痛、神経根引き抜き損傷、疼痛を伴う外傷性単神経障害、疼痛を伴う多発性神経障害、中枢性疼痛症候群、術後痛症候群、複合性局所疼痛症候群、及び/又は、片頭痛若しくは片頭痛の痛みである化合物。
  7. 請求項1〜のいずれか1項に記載の化合物において、
    前記神経因性疼痛は、脊髄損傷及び/又は脊髄挫傷に起因する中枢性疼痛症候群である化合物。
  8. 請求項1〜のいずれか1項に記載の化合物において、
    前記神経因性疼痛は、慢性神経因性疼痛である化合物。
  9. 請求項1〜のいずれか1項に記載の化合物において、
    前記化合物は、神経系の損傷後に始まって、1mg/body〜10g/bodyの1日投与量で投与される化合物。
  10. 神経因性疼痛及び/又は神経因性疼痛症候群の治療において使用するための医薬組成物であって、
    前記医薬組成物は、請求項1〜のいずれか1項に記載の化合物を、遊離形態で又は薬学的に許容される塩若しくは生理機能性誘導体の形態で、薬学的に許容される希釈剤又は担体とともに含み、
    前記神経因性疼痛は、請求項4〜8のいずれか1項に記載の神経因性疼痛及び/又は神経因性疼痛症候群である医薬組成物。
  11. 請求項10に記載の医薬組成物において、
    前記化合物は、化学式:
    を有する化合物、又は、その薬学的に許容される塩、溶媒和物、互変異性体、立体異性体である医薬組成物。
JP2013535311A 2010-10-29 2011-10-28 神経因性疼痛におけるマロノニトリルアミドの使用 Active JP6257326B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40819510P 2010-10-29 2010-10-29
US61/408,195 2010-10-29
EP10014122 2010-10-29
EP10014122.5 2010-10-29
PCT/EP2011/005452 WO2012055567A2 (en) 2010-10-29 2011-10-28 Use of malononitrilamides in neuropathic pain

Publications (3)

Publication Number Publication Date
JP2013545730A JP2013545730A (ja) 2013-12-26
JP2013545730A5 true JP2013545730A5 (ja) 2014-10-16
JP6257326B2 JP6257326B2 (ja) 2018-01-10

Family

ID=44992853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013535311A Active JP6257326B2 (ja) 2010-10-29 2011-10-28 神経因性疼痛におけるマロノニトリルアミドの使用

Country Status (16)

Country Link
US (2) US20130217737A1 (ja)
EP (1) EP2632451B1 (ja)
JP (1) JP6257326B2 (ja)
CN (1) CN103179962B (ja)
CA (1) CA2814371C (ja)
DK (1) DK2632451T3 (ja)
ES (1) ES2655084T3 (ja)
HR (1) HRP20171848T1 (ja)
HU (1) HUE034890T2 (ja)
LT (1) LT2632451T (ja)
NO (1) NO2632451T3 (ja)
PL (1) PL2632451T3 (ja)
PT (1) PT2632451T (ja)
RS (1) RS56713B1 (ja)
SI (1) SI2632451T1 (ja)
WO (1) WO2012055567A2 (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
ES2797624T3 (es) 2012-05-23 2020-12-03 Cellix Bio Private Ltd Composición para el tratamiento de la enfermedad inflamatoria intestinal
WO2013175344A2 (en) * 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CA2873098A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
AU2014407862B2 (en) 2014-09-29 2020-03-26 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (en) 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and pain
MA45202B1 (fr) * 2016-09-24 2022-04-29 Kbp Biosciences Co Ltd Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
PL3928772T3 (pl) 2020-06-26 2024-10-07 Algiax Pharmaceuticals Gmbh Kompozycja nanocząstkowa

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
KR100188801B1 (ko) 1990-05-18 1999-06-01 엥겔하르트 라피체 이속사졸-4카복스아미드 및 하이드록시알킬리덴 시아노아세트아미드 및 이들 화합물을 함유하는 약제학적 조성물
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9200275D0 (en) 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2727628B1 (fr) * 1994-12-02 1997-01-10 Roussel Uclaf Application des derives de 3-cycloalkyl-propanamide a titre de medicaments analgesiques
US6566395B1 (en) * 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
CN103153295A (zh) * 2010-08-24 2013-06-12 艾格埃克斯制药有限公司 来氟米特和丙二腈酰胺类似物的新用途

Similar Documents

Publication Publication Date Title
JP2013545730A5 (ja)
HRP20171848T1 (hr) Upotreba malononitrilamida za neuropatsku bol
JP2012530779A5 (ja)
RU2012101947A (ru) Способы лечения и профилактики усталости
JP2016534063A5 (ja)
JP2009504763A5 (ja)
JP2019515908A5 (ja)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
RU2013113634A (ru) Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств
FI3681857T3 (fi) Fluorifenyyli-beeta-hydroksietyyliamiineja ja niiden käyttö hyperglykaemian hoidossa
JP2015524423A5 (ja)
JP2015522018A5 (ja)
US20100087457A1 (en) Dosages and methods for the treatment of cancer
RU2019111096A (ru) Лекарственные формы леводопы для быстрого купирования болезни паркинсона
JP2011518168A5 (ja)
EP2144886A1 (en) Method of treating melanoma
JP2016537432A5 (ja)
JP2014530204A5 (ja)
RU2019102757A (ru) Производные этинила
JP2017516829A5 (ja)
RU2018130097A (ru) Лечение экземы кистей
JP2010509389A (ja) 化学療法剤により誘起された末梢神経毒性の処置に有効なピロロ[1,2−a]イミダゾールジオン
RU2013148627A (ru) Производные тиено [2, 3-d] пиримидина и их применение для лечения аритмии
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
JP2014509637A5 (ja)